Gracell gives sneak peek into leukemia CAR-T cell program ahead of EHA
2023-05-12
细胞疗法临床1期免疫疗法临床结果
Gracell Biotechnologies said Thursday afternoon that its CAR-T treatment for patients with B cell acute lymphoblastic leukemia, or B-ALL, helped clear signs of cancer in seven of nine patients at a median follow-up of over one year.
In a Phase I trial in China of Gracell’s CAR-T treatment, dubbed GC007g, with patients with relapsed B-ALL, all patients went into remission one month after treatment. At a median follow-up of 445 days (with a wide range of follow-up from 218 to 649 days), seven of nine patients remained in remission, while two had a CD19-negative relapse.
Preview
来源: EndPoints
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 168,300+ biopharma pros reading Endpoints daily — and it's free.
SIGN UP
LOG IN
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。